Introduction
Placental function may be assessed in high-risk pregnancies by serum human placental lactogen (HPL), serum estriol and urinary estriol excretion. The results of these tests may be influenced by maternal smoking [16] or drugs, such as corticosteroids [6] , ampicillin [18] , erythromycin [7] and mandelamine [10] . However, for most drugs used by pregnant women little or nothing is known as to whether or not they affect placental function or its biochemical tests. Antiepileptic drugs are powerful inducers of hepatic microsomal enzyme systems [17] and may alter the metabolism of endogeneous steroid hormones [17] as well as interfere with oral contraception [2] . There is a reason to expect effects on placental function or on its biochemical tests, too, particularly on the metabolism of estriol. The present study is a systematic evaluation of the placental function in epileptic women, most of whom took antiepileptic drugs throughout their pregnancies.
Patients and methods

Patients
A prospective study on 144 consecutive singleton pregnancies of more than 32 weeks duration in 134 women with epilepsy was carried out in 1976-79. The patients were seen fortnightly between 32 to 36 weeks of pregnancy, and weekly thereafter.
Controls
After the delivery by each epileptic, one control pair (mother and child) was obtained at the same clinic. A control was selected to be the following parturient who fulfilled the chosen matching criteria, namely maternal age ± 3 years, same parity, same fetal sex, and same social class as determined by the mother's profession using the standard four-step classification of the Helsinki City Bureau of Statistics. The controls thus represented the general parturient population at the clinic during the study period matched for the chosen parameters. Characteristics of the epileptics and their controls appear in Tab. I.
Criteria for possible drag effects
"Placental function" was evaluated by serum HPL, 24-hour urinary total estriol excretion, placental weight and birth weight. The possible effects of antiepileptic drugs on placental function were expected to appear in the following three ways. First, as differences between epileptics and controls; second, as differences among epileptics grouped by the type of their treatment; and third, as correlations (positive or negative) between the serum levels of antiepileptic drugs and the placental variables. The power of the present study was estimated [12] as 90% to detect a difference of 50 grams (i.e. 40 % of the standard deviation) in the mean weight of the placenta between ,ψοιηβη on antiepileptic drugs and the controls at a p-level of 0.05.
Measurements
Serum concentrations of phenytoin, phenobarbitone, primidone and valproate were measured by gas chromatography [13, 15] . Carbamazepine was assessed by spectrophotometry [11] . Total urinary 24-hour estriol excretion was measured by radioimmunoassay [1] and serum HPL by the commercially available Pharmacia kit which is based on the method of LETCHWORTH [14] .
Calculations and statistics
A computer with BMDP-81 statistical programs [9] was used. Geometric means of available values of HPL and estriol were calculated separately for the 9th month (33rd< to 36th week) and the 10th month (37th to 40th week) of pregnancy in each patient. Skewness of the distributions of urinary estriol, serum HPL and antiepileptic drug levels was correctable by logarithmic or power transformations which allowed standard parametric statistical test. Differences in placental function variables among the epileptics grouped by the type of their treatment were tested by one-way analysis of variance. Correlations between the serum levels of antiepileptic drugs and the placental variables were measured by the standard product-moment correlation coefficients. To cope with the spurious correlations expected among the 21 tests of correlation to be performed, a level of significance of -Ty-= 0.0023 was required for any one correlation before considering it genuine [3].
Tab. II. Serum HPL and total urinary 24-h estriol excretion in epileptic women during late pregnancy.
Month of pregnancy Epileptic patients
Reference (18) . F = F-value. P = probability for occurrence of differences at least as large as those observed among the five groups.
Results
No significant differences between the epileptic mothers and the controls were seen with regard to gestational age, placental weight and birth weight (Tab. I). The levels of serum HPL and total urinary 24-hour estriol excretion of women with epilepsy agreed well with the references (Tab. II). No notable differences in the serum HPL, urinary estriol, placental weight or birth weight were observed among the epileptics grouped by their drug regimen (Tab. HI). Serum levels of antiepileptic drugs in late pregnancy were often below the "therapeutic" ranges [8] (Tab. IV). None of the coefficients of correlation between drug levels and serum HPL, urinary estriol, placental weight and birth weight reached the pre-established limit of p = 0.0023 (Tab. V). The positive correlation between serum phenytoin and birthweight (r = 0.25; ρ = 0.015) was reduced after an adjustment for gestational age and sex.
Values below the 2.5th percentile of HPL (in 3 patients) and estriol (in 7) appeared associated with pre-eclampsia and intrauterine growth retardation but not with maternal antiepileptic treatment.
The incidences of pregnancy complications among the 144 epileptics and 144 controls (in parenthesis) were similar: pregnancy-induced hypertension 8% (10%); albuminuria 3% (3%); intrauterine growth retardation, defined as birth weight below the 10th percentile of the Helsinki standard, 9 % (8 %); placental abruption 1 % (1 %).
Discussion
No genuine associations between the types or serum levels of the antiepileptic drugs and serum HPL, urinary estriol excretion, placental weight and birth weight were observed in the present Transformations prior to analysis: Logarithm of HPL and oestriol; square root of phenytoin and phenobarbitone. r = product-moment correlation coefficient. p = two-tailed probability for a coefficient at least as large as observed.
study. This accords with the only similar series previously reported [5] . The inherent variability of HPL and estriol is large, and small changes may remain undetected when the study sample is relatively small.
An exigent level of significance was required before considering any of the observed differences genuine. This was necessary because of the large number of statistical tests performed. In such a situation some sporadic associations are to be expected, and the concentional general level of p < 0.05 is no more valid [3].
The epileptic patients in the present study seldom showed very high serum levels of antiepileptic drugs. The possibility that higher than therapeutic concentrations of antiepileptic drugs might affect placental function cannot thus be excluded.
While long-term use of antiepileptic drugs appears to have little, if any, clinically important effects on placental function or on its biochemical tests, short-term use of phenobarbitone in pre-eclamptic patients may lower serum estriol [4] . Although the present study showed no change in the total urinary 24-hour estriol excretion, it does not exclude induction by the drugs in the metabolism of estriol, such as alterations in the various glucuronide and sulphate conjugates of estriol.
Out-of-range values of placental function tests in epileptic mothers should evidently not be considered harmless biochemical anomalies due to the mother's medication as is the case e.g. for ampicillin [18] . Serum HPL and 24-hour total urinary estriol can be used in the usual manner to assess fetoplacental function in epileptic women who are on long-term treatment with phenytoin, phenobarbitone or carbamazepine in spite of the powerful enzyme induction properties of the drugs.
Summary
Placental function in the presence of antiepileptic drugs was assessed in 144 unselected late pregnancies of women with epilepsy. The most common drugs of the mothers were phenytoin (104 pregnancies), carbamazepine (42) and phenobarbitone (26). 144 control parturients matched for maternal age, parity, fetal sex and social class were also studied.
No significant associations between the types or the serum concentrations of the mother's antiepileptic drugs and her serum HPL, 24-hour total urinary estriol excretion, placental weight or her child's birth weight were observed. However, since the serum levels of antiepileptic drugs were usually within or below the therapeutic ranges the study does not exclude the possibility that Very high drug concentrations might have some effects. The incidences of common pregnancy complications did not differ between epileptics and controls. Serum HPL and urinary estriol values in epileptic women agreed well with the references for normal.
It is concluded that the long-term use of antiepileptic drugs during pregnancy has no clinically important effects on placental function or on its biochemical tests in spite of the enzyme induction properties of these drugs.
Values of serum HPL and 24-hour total urinary estriol excretion can thus be interpreted in the usual manner in women who are on antiepileptic medication. 
